Monoamine Oxidase and Dementia: Treatment with an Inhibitor of MAO-B Activity
| Autor: | Alessandro Agnoli, N. Martucci, Giovanni Fabbrini, Ann E. Buckley, Mario Fioravanti |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Drug
medicine.medical_specialty business.industry Monoamine oxidase Cognitive Neuroscience Treatment duration media_common.quotation_subject medicine.disease Placebo Gastroenterology Psychiatry and Mental health Concomitant Internal medicine medicine Dementia PRIMARY DEGENERATIVE DEMENTIA Monoamine oxidase B Geriatrics and Gerontology business Psychiatry media_common |
| Zdroj: | Dementia and Geriatric Cognitive Disorders. 1:109-114 |
| ISSN: | 1421-9824 1420-8008 |
| Popis: | Patients suffering from Alzheimer type dementia have demonstrated an increase in MAO-B activity. Treatment of these patients with an inhibitor of the monoamine oxidase activity, such as L-Deprenyl (LD), might therefore provide a valid therapeutic intervention. The efficacy of LD was examined in a double-blind, drug versus placebo (PL) study on 20 patients diagnosed between stages 3 and 5 of primary degenerative dementia. Treatment duration was 90 days (5 mg twice a day). All patients underwent clinical, behavioral, and memory evaluations every 30 days. Subjects in the LD group demonstrated an improvement on both attention and memory measures; some of the changes were apparent after only 30 days of treatment. PL patients showed no such improvement and also evidenced a decrease in behavior efficiency during the experimental period. Two patients dropped out of the study, 1 from each treatment group. No differences were found in either the type and number of concomitant treatments or side effects between groups. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|